Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMHFBOG)

Drug Name
SAR231893 Drug Info
Indication
Disease Entry ICD 11 Status REF
Asthma CA23 Phase 3 [1]
Atopic dermatitis EA80 Phase 3 [1]
Cross-matching ID
TTD Drug ID
DMHFBOG

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin 4 receptor alpha (IL4R) TTDWHC3 IL4RA_HUMAN Modulator [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Interleukin 4 receptor alpha (IL4R) DTT IL4R 8.599 8.06 6.589 7.357
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

ICD Disease Classification 14 Disease of the skin
Disease Class ICD-11: EA90 Psoriasis
The Studied Tissue Skin
The Studied Disease Atopic dermatitis [ICD-11:EA90]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin 4 receptor alpha (IL4R) DTT IL4R 1.48E-08 0.76 3.74
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT02134028) Long-Term Safety Evaluation of Dupilumab in Patients With Asthma. U.S. National Institutes of Health.
2 Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013 Jun 27;368(26):2455-66.